• The grading of gliomas and, particularly, considering certain molecular criteria for classifying a grade II or III IDH-wildtype glioma as a grade IV molecular “glioblastoma” (amplification of EGFR and/or mutation of the TERT promoter and/or presence of a gain of chromosome 7 and a loss of chromosome 10) (10);. The gene discussed is IDH1; the disease is central nervous system cancer.